Local hypoxia in tumors, as well as the short lifetime and limited action region of O-1(2), are undesirable impediments for photodynamic therapy (PDT), leading to a greatly reduced effectiveness. To overcome these adversities, a mitochondria-targeting, H2O2-activatable, and O-2-evolving PDT nanoplatform is developed based on Fe-III-doped two-dimensional C3N4 nanofusiform for highly selective and efficient cancer treatment. The ultrahigh surface area of 2D nanosheets enhances the photosensitizer (PS) loading capacity and the doping of Fe-III leads to peroxidase mimetics with excellent catalytic performance towards H2O2 in cancer cells to generate O-2. As such tumor hypoxia can be overcome and the PDT efficacy is improved, whilst at the same time endowing the PDT theranostic agent with an effective T-1-weighted in vivo magnetic resonance imaging (MRI) ability. Conjugation with a mitochondria-targeting agent could further increase the sensitivity of cancer cells to O-1(2) by enhanced mitochondria dysfunction. In vitro and in vivo anticancer studies demonstrate an outstanding therapeutic effectiveness of the developed PDT agent, leading to almost complete destruction of mouse cervical tumor. This development offers an attractive theranostic agent for in vivo MRI and synergistic photodynamic therapy toward clinical applications.
[1]Chinese Acad Sci, Changchun Inst Appl Chem, State Key Lab Electroanalyt Chem, Changchun 130022, Jilin, Peoples R China.
[2]Chinese Acad Sci, Grad Sch, Beijing 100039, Peoples R China.
[3]Jilin Univ, Dept Radiol, China Japan Union Hosp, Changchun 130022, Jilin, Peoples R China.
[4]Sichuan Univ, Dept Chem Engn, Chengdu 610065, Sichuan, Peoples R China.
(8.0+极速模式)